{"id":"NCT01755546","sponsor":"BioDelivery Sciences International","briefTitle":"Long-term Open-Label Safety Study to Evaluate EN3409","officialTitle":"A Phase 3, Open-label, Long-term Study to Evaluate the Safety, Tolerability, and Analgesic Efficacy of BEMAÂ® Buprenorphine in Subjects With Moderate to Severe Chronic Pain Requiring Continuous Around-the-Clock Opioid Analgesia for an Extended Period of Time","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12","primaryCompletion":"2014-10","completion":"2014-11","firstPosted":"2012-12-24","resultsPosted":"2018-09-12","lastUpdate":"2018-10-18"},"enrollment":304,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Low Back Pain","Osteoarthritis","Neuropathic Pain"],"interventions":[{"type":"DRUG","name":"EN3409","otherNames":["Buprenorphine HCI Buccal Film 300-900 mcg twice daily"]}],"arms":[{"label":"EN3409","type":"EXPERIMENTAL"}],"summary":"The purpose of the long-terms study is to evaluate the safety, tolerability, and analgesic efficacy of EN3409 in subjects with moderate to severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.","primaryOutcome":{"measure":"Change From Baseline to Week 48 in Daily Average NRS Pain Intensity Score","timeFrame":"48 weeks","effectByArm":[{"arm":"Overall","deltaMin":0.2,"sd":1.78}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":15},"locations":{"siteCount":57,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":224},"commonTop":["Nausea","Upper respiratory tract infection","Back pain","Headache","Vomiting"]}}